← 홈

ADC · 폐암 (NSCLC)

13개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 13개
ADCSFDAFDABiologicFundación Pública Andaluza para…Deruxtecan-Dlnk Quantificat…Phase 3

Datopotamab deruxtecan (Datopotamab deruxtecan)

Breast Cancer; Metastatic Breast Cancer · Lung Cancer

#LungCancer#ADC#Phase3#FDA승인#항체약물접합체+5
효능 ORR 79%임상시험 44상태 RECRUITING
ADCSFDAFDABiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#FDA승인#항체약물접합체+4
효능 ORR 71.7%임상시험 23상태 RECRUITING
ADCSHotBiologicRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5
효능 ORR 69.7%임상시험 106상태 RECRUITING
ADCSBiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 84상태 RECRUITING
ADCBiologicNovartis PharmaceuticalsPhase 2

Ribociclib (Ribociclib)

KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung · Breast Cancer

#BreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 66.7%임상시험 66상태 RECRUITING
ADCBiologicSuzhou Transcenta Therapeutics …DM1) leading to diabetic ke…Phase 2

Albumin-Paclitaxel (Albumin-Paclitaxel)

Non-small Cell Lung Cancer Metastatic; First-line Treatment · Breast Cancer Early Stage Breast Cancer

#BreastCancerEarlyStageBreastCanc#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 79.5%임상시험 63상태 RECRUITING
ADCBiologicFondazione per la Medicina Pers…Phase 2

Selpercatinib (Selpercatinib)

Breast Cancer; Gastrointestinal Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 100%임상시험 38상태 ACTIVE
ADCBiologicstaleMerck Sharp & Dohme LLCPhase 3

Patritumab Deruxtecan (Patritumab Deruxtecan)

Lung Neoplasm Malignant · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 56%임상시험 28상태 RECRUITING
ADCBiologicstaleEMD Serono Research & Developme…Phase 2

Tepotinib (Tepotinib)

Non-small Cell Lung Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 54.7%임상시험 28상태 ACTIVE
ADCBiologicstaleBioAtla, Inc.Phase 2

CAB-ROR2-ADC (CAB-ROR2-ADC)

Non Small Cell Lung Cancer; Triple Negative Breast Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 3상태 ACTIVE
ADCBiologicstaleEnliven TherapeuticsPhase 1

ELVN-002 (ELVN-002)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 2상태 RECRUITING
ADCBiologicstaleMersana TherapeuticsPhase 1

XMT-1522 (XMT-1522)

Advanced Breast Cancer; Advanced Nonsmall Cell Lung Cancer · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleMediLink Therapeutics (Suzhou) …Phase 2

YL202 should be intravenously infused (YL202 should be intravenously infused)

NSCLC; Breast Cancer · NSCLC

#NSCLC#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 RECRUITING